Literature DB >> 2545922

Mutational analysis of autonomously functioning trans-activating peptides encoded by adenovirus E1A: evidence for two subdomains.

R Pusztai1, P M Loewenstein, M Green.   

Abstract

We have shown previously that a chemically synthesized adenovirus E1A region 3 peptide of 49 amino acids, protein domain 3 (PD3; residues 140 to 188 of the 289-amino-acid protein), trans activates viral genes in vitro and in vivo. To study structure-function relationships, we synthesized N-terminal deletion and cysteine substitution mutant peptides and tested their activities in a cell microinjection assay. Peptides lacking 1 to 12 N-terminal residues exhibited 5- to 50-fold-reduced molar specific activities, whereas those lacking 16 or 18 residues were inactive. Substitution of each of five PD3 cysteine residues with alanine resulted in substantial losses of activity: mutants in the PD3 N-terminal portion showed 40 to 55% of wild-type activity but required a 20-fold-higher concentration than PD3, whereas those in the C-terminal half were as much less active. These peptide mutant studies suggest the existence of two PD3 functional regions: one, localized in the C-terminal 70 to 75% of the molecule, is essential for trans activation; the other, localized in the N-terminal 25 to 30%, can be overridden to a significant extent at high peptide concentrations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545922      PMCID: PMC250930          DOI: 10.1128/JVI.63.8.3516-3518.1989

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  Transcription activation by the adenovirus E1a protein.

Authors:  J W Lillie; M R Green
Journal:  Nature       Date:  1989-03-02       Impact factor: 49.962

2.  Potential metal-binding domains in nucleic acid binding proteins.

Authors:  J M Berg
Journal:  Science       Date:  1986-04-25       Impact factor: 47.728

Review 3.  Adenovirus promoters and E1A transactivation.

Authors:  A J Berk
Journal:  Annu Rev Genet       Date:  1986       Impact factor: 16.830

4.  Identification of separate domains in the adenovirus E1A gene for immortalization activity and the activation of virus early genes.

Authors:  E Moran; B Zerler; T M Harrison; M B Mathews
Journal:  Mol Cell Biol       Date:  1986-10       Impact factor: 4.272

5.  Relationship between the transforming and transcriptional regulatory functions of adenovirus 2 E1a oncogene.

Authors:  M N Kuppuswamy; G Chinnadurai
Journal:  Virology       Date:  1987-07       Impact factor: 3.616

6.  An adenovirus E1a protein region required for transformation and transcriptional repression.

Authors:  J W Lillie; M Green; M R Green
Journal:  Cell       Date:  1986-09-26       Impact factor: 41.582

7.  Functional domains of adenovirus type 5 E1a proteins.

Authors:  J W Lillie; P M Loewenstein; M R Green; M Green
Journal:  Cell       Date:  1987-09-25       Impact factor: 41.582

8.  An adenovirus type 5 E1A protein with a single amino acid substitution blocks wild-type E1A transactivation.

Authors:  G M Glenn; R P Ricciardi
Journal:  Mol Cell Biol       Date:  1987-03       Impact factor: 4.272

9.  Sequence analysis in the E1 region of adenovirus type 4 DNA.

Authors:  O Tokunaga; T Yaegashi; J Lowe; L Dobbs; R Padmanabhan
Journal:  Virology       Date:  1986-12       Impact factor: 3.616

10.  Repetitive zinc-binding domains in the protein transcription factor IIIA from Xenopus oocytes.

Authors:  J Miller; A D McLachlan; A Klug
Journal:  EMBO J       Date:  1985-06       Impact factor: 11.598

View more
  2 in total

Review 1.  Adenovirus-E1A proteins transform cells by sequestering regulatory proteins.

Authors:  D S Peeper; A Zantema
Journal:  Mol Biol Rep       Date:  1993-04       Impact factor: 2.316

2.  The adenoviral E1A N-terminal domain represses MYC transcription in human cancer cells by targeting both p300 and TRRAP and inhibiting MYC promoter acetylation of H3K18 and H4K16.

Authors:  Ling-Jun Zhao; Paul M Loewenstein; Maurice Green
Journal:  Genes Cancer       Date:  2016-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.